Real-World Efficacy of Midostaurin in Aggressive Systemic Mastocytosis

Real-World Efficacy of Midostaurin in Aggressive Systemic Mastocytosis

In April 2017 midostaurin was approved by the US Food and Drug Administration for the treatment of patients with aggressive systemic mastocytosis (ASM). So far, very limited real world data on its efficacy is available. Thirteen patients aged from 48 to 79 years, who received midostaurin in the earl...

Full description

Bibliographic Details
Main Authors: Aneta Szudy-Szczyrek, Oliwia Bachanek-Mitura, Tomasz Gromek, Karolina Chromik, Andrzej Mital, Michał Szczyrek, Witold Krupski, Justyna Szumiło, Zuzanna Kanduła, Grzegorz Helbig, Marek Hus
Format: Article
Language:English
Published: MDPI AG 2021-03-01
Series:Journal of Clinical Medicine
Subjects:
aggressive systemic mastocytosis
midostaurin
mast cells
tryptase
<i>KIT D816V</i> mutation
Online Access:https://www.mdpi.com/2077-0383/10/5/1109

Similar Items

Similar Items